Baseline characteristics of 626 patients with newly diagnosed MM
Characteristic . | n/N (%) . | Median (range) . |
---|---|---|
Age at diagnosis, y | 57 (26-83) | |
Male | 382/626 (61) | |
ISS stage | ||
I | 122/626 (19) | |
II | 236/626 (38) | |
III | 268/626 (43) | |
Cytogenetics abnormalities by iFISH | ||
High risk* | 172/557 (31) | |
Standard risk† | 385/557 (69) | |
M-component | ||
IgG | 307/626 (49) | |
IgA | 151/626 (24) | |
Light chain | 119/626 (19) | |
Other | 49/626 (8) | |
First-line therapy | ||
IMiDs‡ | 236/626 (38) | |
PIs‡ | 401/626 (64) | |
First-line transplantation§ | 182/626 (29) | |
Best response to first-line therapy | ||
CR | 265/626 (42) | |
VGPR | 161/626 (26) | |
PR | 133/626 (21) | |
TBR, mo | 3.1 (0.7-19.0) | |
DBR, mo | 21.2 (1.5-130.0) |
Characteristic . | n/N (%) . | Median (range) . |
---|---|---|
Age at diagnosis, y | 57 (26-83) | |
Male | 382/626 (61) | |
ISS stage | ||
I | 122/626 (19) | |
II | 236/626 (38) | |
III | 268/626 (43) | |
Cytogenetics abnormalities by iFISH | ||
High risk* | 172/557 (31) | |
Standard risk† | 385/557 (69) | |
M-component | ||
IgG | 307/626 (49) | |
IgA | 151/626 (24) | |
Light chain | 119/626 (19) | |
Other | 49/626 (8) | |
First-line therapy | ||
IMiDs‡ | 236/626 (38) | |
PIs‡ | 401/626 (64) | |
First-line transplantation§ | 182/626 (29) | |
Best response to first-line therapy | ||
CR | 265/626 (42) | |
VGPR | 161/626 (26) | |
PR | 133/626 (21) | |
TBR, mo | 3.1 (0.7-19.0) | |
DBR, mo | 21.2 (1.5-130.0) |
iFISH, interphase fluorescent in situ hybridization.
High-risk cytogenetic abnormalities (CAs) were defined as the presence of 20% or more del(17p) or 10% or more t(4;14), t(14;16), or t(14;20) in screened plasma cells.
Standard-risk CAs defined by the absence of high-risk CAs.
A total of 11 patients who received IMiDs combined with PIs were counted twice.
First-line transplantation was defined as transplantation within 12 months of first-line therapy.